{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:22:51Z","timestamp":1786998171314,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.xkme.2020.06.007","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T12:11:56Z","timestamp":1596629516000},"page":"652-656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Use of Eculizumab in Transplant-Associated Thrombotic Microangiopathy in a Patient With Polycystic Kidney Disease Immediately Post\u2013Kidney Transplant: A Case Report"],"prefix":"10.1016","volume":"2","author":[{"given":"Amandeep","family":"Godara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Migliozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Pilichowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitender","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig E.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.xkme.2020.06.007_bib1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/ajkd.2003.50058","article-title":"De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy","volume":"41","author":"Schwimmer","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.xkme.2020.06.007_bib2","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ajkd.2003.07.008","article-title":"Thrombotic microangiopathy after renal transplantation in the United States","volume":"42","author":"Reynolds","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.xkme.2020.06.007_bib3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2020.06.007_bib4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00007890-199902270-00009","article-title":"FK506-associated thrombotic microangiopathy: report of two cases and review of the literature","volume":"67","author":"Trimarchi","year":"1999","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.xkme.2020.06.007_bib5","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.transproceed.2014.07.062","article-title":"Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation","volume":"46","author":"Nava","year":"2014","journal-title":"Transplant Proc"},{"issue":"26","key":"10.1016\/j.xkme.2020.06.007_bib6","first-page":"2600","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.xkme.2020.06.007_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.transproceed.2016.11.008","article-title":"Eculizumab and belatacept for de novo atypical hemolytic uremic syndrome associated with CFHR3-CFHR1 deletion in a kidney transplant recipient: a case report","volume":"49","author":"Dedhia","year":"2017","journal-title":"Transplant Proc"},{"issue":"1","key":"10.1016\/j.xkme.2020.06.007_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.transproceed.2016.10.013","article-title":"Efficacy of eculizumab therapy for atypical hemolytic uremic syndrome recurrence and antibody-mediated rejection progress after renal transplantation with preformed donor-specific antibodies: case report","volume":"49","author":"Yamamoto","year":"2017","journal-title":"Transplant Proc"},{"issue":"suppl 1","key":"10.1016\/j.xkme.2020.06.007_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nep.12768","article-title":"Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab","volume":"21","author":"Ikeda","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.xkme.2020.06.007_bib10","unstructured":"FDA Belatacept prescribing information. 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125288s070lbl.pdf. Accessed August 19, 2020."},{"issue":"8","key":"10.1016\/j.xkme.2020.06.007_bib11","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1111\/j.1600-6143.2010.03178.x","article-title":"De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection","volume":"10","author":"Satoskar","year":"2010","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.xkme.2020.06.007_bib12","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/j.1600-6143.2011.03754.x","article-title":"Delayed graft function in the kidney transplant","volume":"11","author":"Siedlecki","year":"2011","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.xkme.2020.06.007_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.trre.2013.07.003","article-title":"Targeted strategies in the prevention and management\u00a0of atypical HUS recurrence after kidney transplantation","volume":"27","author":"Zuber","year":"2013","journal-title":"Transplant Rev (Orlando)"},{"issue":"4","key":"10.1016\/j.xkme.2020.06.007_bib14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10157-018-1655-2","article-title":"Survey Committee for TA-TMA of the Japan Society for Transplantation Survey of thrombotic microangiopathy within 1 week after kidney transplantation between 2010 and 2015 in Japan","volume":"23","author":"Satoh","year":"2019","journal-title":"Clin Exp Nephrol"},{"issue":"9","key":"10.1016\/j.xkme.2020.06.007_bib15","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1016\/j.transproceed.2013.07.060","article-title":"Case series: hemolytic uremic syndrome--another cause of transplant dysfunction","volume":"45","author":"Ali","year":"2013","journal-title":"Transplant Proc"},{"issue":"8","key":"10.1016\/j.xkme.2020.06.007_bib16","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation","volume":"8","author":"Le Quintrec","year":"2008","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.xkme.2020.06.007_bib17","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/tri.13022","article-title":"Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis","volume":"30","author":"Legendre","year":"2017","journal-title":"Transpl Int"},{"issue":"5","key":"10.1016\/j.xkme.2020.06.007_bib18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5500\/wjt.v8.i5.122","article-title":"Thrombotic microangiopathy after renal transplantation: current insights in de novo and recurrent disease","volume":"8","author":"Abbas","year":"2018","journal-title":"World J Transplant"},{"issue":"3","key":"10.1016\/j.xkme.2020.06.007_bib19","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.xkme.2020.06.007_bib20","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1681\/ASN.2015010012","article-title":"Rare variants in the complement factor H-related protein 5 gene contribute to genetic susceptibility to IgA nephropathy","volume":"27","author":"Zhai","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2020.06.007_bib21","first-page":"648","article-title":"The known unknown: the challenges of genetic variants of uncertain significance in clinical practice","volume":"4","author":"Hoffman-Andrews","year":"2017","journal-title":"J\u00a0Law Biosci"},{"issue":"5","key":"10.1016\/j.xkme.2020.06.007_bib22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"7","key":"10.1016\/j.xkme.2020.06.007_bib23","article-title":"Outcomes of kidney transplant patients with atypical hemolytic uremic syndrome treated with eculizumab: a systematic review and meta-analysis","volume":"8","author":"Gonzalez Suarez","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.xkme.2020.06.007_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2020.06.007_bib25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.xkme.2020.06.007_bib26","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"French Study Group for aHUS\/C3G Collaborators Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2020.06.007_bib27","first-page":"310","article-title":"Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome","volume":"10","author":"Macia","year":"2017","journal-title":"Clin Kidney J"},{"issue":"5","key":"10.1016\/j.xkme.2020.06.007_bib28","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.ajkd.2017.05.017","article-title":"Thrombotic microangiopathy: a multidisciplinary team approach","volume":"70","author":"Gordon","year":"2017","journal-title":"Am J Kidney Dis"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059520301618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059520301618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:20:04Z","timestamp":1762910404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059520301618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S2590059520301618"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2020.06.007","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Eculizumab in Transplant-Associated Thrombotic Microangiopathy in a Patient With Polycystic Kidney Disease Immediately Post\u2013Kidney Transplant: A Case Report","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2020.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}